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N eonatal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome that primarily occurs after in utero exposure to opioids. In the US, it is estimated that 1 infant is born every 25 minutes with NAS, representing $1.5 billion in additional hospital charges.
1,2 NAS is increasing in frequency and can represent as many as 50% of admissions to some neonatal intensive care units. 3 Gabapentin was approved in the US in 1993 for the treatment of partial seizures and has been prescribed increasingly for a number of other conditions. Recently, nonprescription gabapentin use has been reported among opioid abusers to potentiate the opioid high. [4] [5] [6] In this retrospective case series, we describe infants born to mothers at our institution who have used both opioids and gabapentin, describe a unique withdrawal syndrome, and report a successful treatment strategy.
Methods
We searched the hospital database at Marshall University's major teaching institution, Cabell Huntington Hospital, for all admissions of infants born to mothers who had used both opioids and gabapentin during their pregnancies. The study was approved by the Institutional Review Board of Marshall University. This hospital serves as a tertiary care perinatal referral center for Southern West Virginia, Eastern Kentucky, and Southeastern Ohio. On admission for delivery, all mothers had a urine drug screen for amphetamine, barbiturates, benzodiazepines, cocaine, methadone, opiates (including codeine, dihydrocodeine, hydrocodone, hydromorphone, levallorphan, levorphanol, meperidine, 6-acetylmorphine, morphine-3-glucuronide, nalorphine, naloxone, oxycodone, and oxymorphone), phencyclidine, cannabinoids, buprenorphine, oxycodone, and tricyclic antidepressants. If a mother had a positive drug screen at delivery, a history of a positive screen during pregnancy, or a past history of drug abuse, a sample of umbilical cord tissue was submitted for analysis of drugs, including amphetamines, barbiturates, buprenorphine, benzodiazepines, cocaine, methadone, meperidine, opiates (6-monoacetylmorphine, meconin, codeine, hydrocodone, hydromorphone, morphine), phencyclidine, oxycodone, propoxyphene, cannabinoids, and tramadol (United States Drug Testing Laboratories, Des Plaines, Illinois). Currently, cord tissue gabapentin levels are not offered by the United States Drug Testing Laboratories; however, we have now incorporated a gabapentin homogeneous enzyme immunoassay into our urine drug screens (ARK Diagnostics, Inc, Sunnyvale, California). If the cord tissue screen was positive, the mother was interviewed separately by the attending physician or nurse and a social worker regarding other drugs taken during pregnancy, specifically gabapentin. These interviews were done between 5 and 10 days postpartum when the cord tissue results had been reported.
Babies at risk for NAS were managed using the Finnegan Scoring System and therapy was begun with methadone when 3 consecutive scores equaled or exceeded 8. Dosage of methadone was begun at 0.05 mg/kg per dose every 6 hours. The dosage was increased when the average score for the preceding 24 hours exceeded 12. Dosage remained unchanged for average scores of 8-12 and lowered incrementally every 24-48 hours for average scores of less than 8. Methadone was weaned over 9 steps by reduction of dosage by approximately 10% for the initial 4 steps, followed by alternating expansion of the interval and reduction of dosage until the final step of 0.01 mg/kg every 24 hours. If scores did not decrease after increasing methadone to 0.05 mg/kg every 3 hours, clonidine was added at 0.5 mg/kg per dose every 6 hours. Clonidine could be increased to 2 mg/kg per dose every 6 hours.
Results
In 2015, 2810 newborn infants were delivered at Cabell Huntington Hospital. Four hundred and twenty cord samples were positive for 1 or more nonprescribed drugs or prescribed methadone or buprenorphine. Of the 288 infants with opioids present in the cord tissue sample, 188 (73.4%)
DOL
Day of life GABA Gamma-aminobutyric acid NAS Neonatal abstinence syndrome required medication treatment for NAS. All 19 infants who had a positive umbilical cord analysis for opioids and maternal admission of the use of nonprescription gabapentin during pregnancy required treatment. Of these infants, 9 were managed with methadone alone and 10 required additional therapy.
The following patient is representative of these 10 infants. Patient 1 was delivered at 37 weeks by dates to a 28-year-old mother with a history of heroin use, positive for hepatitis C virus infection, and no prenatal care. Cord drug screen was positive for heroin and hydromorphone. The baby developed NAS and was treated with methadone on day of life (DOL) 3. The methadone dose was increased to 0.05 mg/kg every 3 hours. Clonidine was added on DOL 7 owing to persistent scores of greater than 12. The baby was noted to have an unusual behavioral pattern including tongue thrusting, wandering eye movements, back arching, and continuous extremity movement, even while being held.
Electroencephalography and magnetic resonance imaging scan were normal. The mother was re-interviewed on DOL 10 and admitted to using gabapentin from 600 to 3000 mg/day since the first month of pregnancy. The baby had persistence of the continuous extremity movements and Finnegan scores of greater than 12. Gabapentin was begun at 5 mg/kg per day in 2 doses and within 48 hours Finnegan scores decreased to less than 8 and abnormal neurologic movements ceased. Clonidine was discontinued over 4 days and methadone was weaned to 0.02 mg every 8 hours. Gabapentin was then decreased by 25% every 4 days and this was coordinated with weaning the methadone every 48 hours. The baby was off all medications by DOL 45.
In total, 19 infants were identified whose mothers were on opioids and gabapentin with doses of gabapentin ranging from 600-12 500 mg/day. Of these infants, 15 demonstrated the same behaviors, including tongue thrusting, wandering eye movements while awake, back arching, and continuous extremity movements. Electroencephalograms were done on 5 and read as normal. Ten of these infants were unable to wean from methadone, and gabapentin was added to their treatment. Their course and history are illustrated in the Table. All 10 manifested tongue thrusting, wandering eye movements, back arching, and continuous extremity movements. Initiation of gabapentin therapy occurred on DOL 7-26. The decision to begin gabapentin therapy depended on admitted prenatal use, a failure to wean or escalation of methadone, and sustained behavioral changes. All these infants were weaned to methadone 0.02 mg every 8 hours (step 6), followed by gabapentin weaning by 25% every 4 days coordinated with methadone weaning every 48 hours. More rapid gabapentin weaning was associated with increasing Finnegan scores and relapsing of abnormal neurologic behavior. The remaining 9 infants were managed with methadone weaning alone. Five of these infants manifested similar abnormal symptoms, but these were less severe. The average length of medication therapy for those infants treated with gabapentin was 47 ± 8.8 days.
Discussion
Gabapentin is widely used in adults and children for partial seizures and neuropathic pain syndromes. It is also used offlabel for a number of other conditions, including refractory chronic cough, diabetic neuropathy, hot flashes, postoperative pain, restless legs syndrome, and social anxiety disorder. It is a gamma-aminobutyric acid (GABA) analog but does not bind to GABA receptors. Although gabapentin does not interact with the GABA neurotransmitter system directly, it does exert a neuronal inhibitory effect by blocking voltage-dependent calcium channels, resulting in central nervous system effects. 7 Studies in the neonate have shown an umbilical cord/ maternal plasma concentration ratio of close to 2, indicating an active transport of gabapentin across the placenta. In addition, the plasma half-life in the neonate is 14 hours compared with 5-7 hours in the adult. These observations suggest an accumulation of gabapentin in the fetal compartment. 8 Historically, gabapentin was marketed as an agent that had no significant risk for dependence or abuse and was not classified as a scheduled medication. A recent meta-analysis reviews a number of documented cases of gabapentin abuse, dependence, and withdrawal. 6 Two studies have reported that 22% of patients taking opioids cross-abused gabapentin. 4, 9 A third study found that 26% of patients who were addicted to opioids reported illegally obtaining and using gabapentin. 5 The reason for this association is unclear, but these studies hypothesize the potentiation of the opioid high with gabapentin.
Two hypotheses for the mechanism for opioid potentiation by gabapentin have been proposed based on animal studies. The first is that gabapentin seems to increase endogenous opioid peptide levels in the amygdala of freely moving rats. 10 The amygdala is a nucleus within the addiction circuitry in the brain that may be important for processing positive reward expectancy for opioids. 11 The second is that gabapentin enhances the antinociceptive effect of opioids through upregulation of the anti-inflammatory cytokine interleukin-10 and inhibition of proinflammatory cytokines in the rat spinal cord. 12 Mersfelder and Nichols 6 recently reviewed the literature on gabapentin abuse and withdrawal and reported that the onset of withdrawal symptoms in adults is between 12 hours and 7 days after cessation of use. Symptoms included some form of agitation in more than one-half, and confusion and disorientation in 45% of the cases. Other common symptoms included diaphoresis (36%), nonspecified gastrointestinal symptoms (23%), tremor, tachycardia, hypertension (each at 18%), and insomnia (14%). Whereas the above symptoms are reported most commonly, individual cases have also presented as akathisia, catatonia, and seizures. 6 Two reports have described infants born to mothers treated with gabapentin for seizures during pregnancy. One study included 16 infants born to mothers on gabapentin monotherapy; 1 infant was born with a single kidney, and the outcome was normal for the others. 13 The second study examined 6 infants born to mothers on 900-3200 mg gabapentin for seizures or pain syndrome. One infant had hypotonia and cyanosis at 8 hours of age, and was subsequently normal and discharged at 4 days of age. The remaining 5 infants were unremarkable. 8 No infant in either study was reported to have withdrawal symptoms.
A single case of withdrawal has been described in a neonate born to a mother on baclofen, gabapentin (1800 mg/day), and oxybutynin. The infant showed signs of drug withdrawal by 24 hours of life, including sneezing, irritability, jitteriness, and loose stools. She was treated initially with lorazepam without improvement. Finnegan scores ranged from 15 to 19. She was begun on gabapentin at 5 mg/kg every 12 hours. Scores improved rapidly after initiation of gabapentin treatment. The gabapentin was gradually weaned and discontinued on DOL 48. 14 The main limitation of our study is that we cannot be certain that there is a causal link between combined prenatal gabapentin and opioid exposure and the atypical NAS we observed. Only 15 of the 19 exposed infants were recognized to have the atypical symptoms. We relied only on maternal history, which might have underestimated gabapentin use, and it is possible many more infants were exposed without the unique behavioral pattern.
Another limitation of our study is that 6 of our 10 infants who required gabapentin therapy had more than 1 nonprescribed substance present in their cord tissue sample that may have contributed to the development of the observed atypical behavior.
In conclusion, we have described 19 infants born to mothers who used both opioids and gabapentin during pregnancy, which represented 10% of the babies born to opioid-addicted mothers who developed NAS at our institution. Although these infants could represent an exaggeration of opioid withdrawal, we suggest that the failure to control symptoms with methadone alone, the unique behavioral features noted in the majority of our infants, and the rapid improvement with the addition of gabapentin therapy in one-half of the co-exposed infants might result from the combination of opioid and gabapentin use during pregnancy.
Gabapentin and opioid use could be more prevalent in pregnant mothers than recognized previously. Our recommendation is that physicians be alert to this possibility and recognize the atypical withdrawal behaviors associated with this coexposure. Given how little we know about the effects of gabapentin in the neonate, we recommend caution in its use in co-exposed infants unless symptoms are not controlled by traditional NAS therapies. If used, we found that reducing the dose of gabapentin by more than 25% every 4 days can result in recurrence of atypical withdrawal symptoms. ■ Submitted for publication Jun 6, 2016; last revision received Oct 5, 2016; accepted Nov 1, 2016 
